Inventiva (NASDAQ:IVA) Stock Rating Raised to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Inventiva from “sell” to “hold,” while the broader analyst consensus remains “Buy” with a $15.86 target price.
• Inventiva shares opened at $3.56, below their 50-day and 200-day moving averages, and the company reported a quarterly loss of $0.14 per share on $0.75 million in revenue.
• Institutional investors own approximately 19.06% of Inventiva, whose lead drug candidate, lanifibranor, is being developed to treat MASH, a serious form of fatty liver disease.

Inventiva (NASDAQ:IVA - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

IVA has been the topic of several other reports. Guggenheim boosted their price objective on shares of Inventiva from $11.00 to $14.00 and gave the stock a "buy" rating in a report on Tuesday, September 15th. Cantor Fitzgerald assumed coverage on shares of Inventiva in a report on Friday, July 17th. They set an "overweight" rating on the stock. Piper Sandler reiterated an "overweight" rating on shares of Inventiva in a research report on Wednesday, September 16th. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research note on Friday, July 17th. Finally, Truist Financial upped their price target on shares of Inventiva from $13.00 to $18.00 and gave the company a "buy" rating in a research report on Friday. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $15.86.

Inventiva Price Performance

Shares of NASDAQ IVA opened at $3.56 on Friday. The stock's 50-day moving average is $4.33 and its 200 day moving average is $4.66. Inventiva has a 1-year low of $3.11 and a 1-year high of $7.98.

Inventiva (NASDAQ:IVA - Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.14) earnings per share (EPS) for the quarter. The business had revenue of $0.75 million during the quarter. Equities research analysts expect that Inventiva will post -0.81 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. NEXTBio Capital Management LP bought a new stake in Inventiva during the 4th quarter valued at $6,039,000. Propel Bio Management LLC purchased a new stake in Inventiva during the 4th quarter valued at $4,650,000. Eventide Asset Management LLC bought a new stake in Inventiva in the 4th quarter worth $1,155,000. Seven Fleet Capital Management LP bought a new stake in Inventiva in the 1st quarter worth $1,111,000. Finally, Persistent Asset Partners Ltd purchased a new position in shares of Inventiva in the fourth quarter valued at about $603,000. 19.06% of the stock is owned by hedge funds and other institutional investors.

About Inventiva

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Dijon, France. The company develops oral small-molecule therapies for chronic metabolic and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva's lead product candidate is lanifibranor, an investigational pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease associated with metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.